Catalog No. Size 价格库存数量
S0223-2 2mg solid ¥2,270
S0223-10 10mg solid ¥9,080


Reveromycin A, a benzoquinoid antibiotic isolated from the genus Streptomyces, is a selective inhibitor of protein synthesis in eukaryotic cells. Reveromycin A inhibits bone resorption by inducing apoptosis specifically in osteoclasts. Reveromycin A has antiproliferative activity against tumor cell lines and antifungal activity.

Product information

CAS Number: 134615-37-5

Molecular Weight: 660.79

Formula: C36H52O11

Chemical Name: (2E, 4S, 5S, 6E, 8E)-10-[(2R, 3S, 6S, 8S, 9R)-9-butyl-8-[(1E, 3E)-4-carboxy-3-methylbuta-1, 3-dien-1-yl]-9-[(3-carboxypropanoyl)oxy]-3-methyl-1, 7-dioxaspiro[5.5]undecan-2-yl]-5-hydroxy-4, 8-dimethyldeca-2, 6, 8-trienoic acid

Smiles: CCCC[C@]1(CC[C@]2(CC[C@H](C)[C@@H](C/C=C(\C)/C=C/[C@H](O)[C@@H](C)/C=C/C(O)=O)O2)O[C@H]1/C=C/C(/C)=C/C(O)=O)OC(=O)CCC(O)=O


InChi: InChI=1S/C36H52O11/c1-6-7-19-35(47-34(44)17-16-32(40)41)21-22-36(46-30(35)14-10-25(3)23-33(42)43)20-18-27(5)29(45-36)13-9-24(2)8-12-28(37)26(4)11-15-31(38)39/h8-12,14-15,23,26-30,37H,6-7,13,16-22H2,1-5H3,(H,38,39)(H,40,41)(H,42,43)/b12-8+,14-10+,15-11+,24-9+,25-23+/t26-,27-,28-,29+,30-,35+,36-/m0/s1

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: Soluble in DMSO

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥360 days if stored properly.

Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

Reveromycin A inhibits protein synthesis in osteoclasts (OCs) by selectively blocking enzymatic activity of isoleucyl-tRNA synthetase. Reveromycin A (0.3-30 μM; for 24 h) induces apoptosis in OCs through inhibition of protein synthesis.

In Vivo:

Reveromycin A (20 mg/kg; twice daily; i.v.; for 3 days) significantly decreases numbers of OCs without affecting numbers of osteoblasts in normal 4-week-old male Sprague-Dawley rats.


  1. H Takahashi , et al. Reveromycins, new inhibitors of eukaryotic cell growth. II. Biological activities. J Antibiot (Tokyo). 1992 Sep;45(9):1414-9.
  2. Je-Tae Woo, et al. Reveromycin A, an agent for osteoporosis, inhibits bone resorption by inducing apoptosis specifically in osteoclasts. Proc Natl Acad Sci U S A. 2006 Mar 21;103(12):4729-34.

Products are for research use only. Not for human use.


Recently viewed